Cleveland.com: Biotech startup Lamassu, Cleveland Clinic aim to treat rare cancers with just three pills a month

11/05/2024

CLEVELAND, Ohio — A biotech startup from North Carolina thinks Cleveland is where it will develop how to treat rare cancers with just three pills a month.

If effective, Lamassu Biotech’s innovative gene therapy could eliminate the need for surgery or chemotherapy for some types of hard-to-treat cancer, said CEO Dr. Gabi Hanna.

CLICK HERE to read the full story from Cleveland.com.

READ MORE

06/26/2025

Crain’s Cleveland Business: The U.S. Is Losing Its Biotech Edge

Biotech is one of America’s most critical innovation sectors, but it is facing serious headwinds. Since COVID-19, the industry has been hammered by falling investor confidence, sluggish IPO markets, and rising international competition.  If we do not act to strengthen...

READ THE ARTICLE
06/06/2025

Crain’s Cleveland Business: Cleveland biotech company secures $2.7M in NIH funding

Lamassu Biotech, a company with its “second headquarters” in Cleveland, has received a $2.7 million grant from the National Institutes of Health (NIH). The funds will help support the development of a novel treatment protocol for acute pancreatitis in canines....

READ THE ARTICLE
06/04/2025

Cleveland Business Journal: Lamassu Biotech’s dog treatment could lead to human pancreatitis breakthrough, backed by NIH funds

Lamassu Biotech, the North Carolina-based biopharmaceutical company that opened a Cleveland office last year, has received a $2.7 million grant from the National Institutes of Health to help develop its therapy for dogs with acute pancreatitis. The therapeutic, called RABI-767, also could...

READ THE ARTICLE